Psilocybin for Depression in MCI/AD (NCT04123314)

Overview

flowchart TD
    Psilocybin_for_Depression_in_M["Psilocybin for Depression in MCI/AD NCT04123314"] -->|"references"| BDNF["BDNF"]
    Psilocybin_for_Depression_in_M["Psilocybin for Depression in MCI/AD NCT04123314"] -->|"references"| TLR4["TLR4"]
    style Psilocybin_for_Depression_in_M fill:#4fc3f7,stroke:#333,color:#000

This Phase 1 pilot study examines whether psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer’s Disease (AD). This represents a novel psychedelic approach to treating depression in neurodegenerative disease populations.

Trial Details

Mechanism of Action

Psilocybin exerts its effects through the following mechanisms:

1. 5-HT2A Receptor Agonism — Psilocybin is metabolized to psilocin, which acts as a partial agonist at serotonin 5-HT2A receptors

2. Default Mode Network Modulation — Psychedelics reduce activity in the default mode network (DMN), which is hyperactive in depression and AD

3. Neuroplasticity Enhancement — 5-HT2A activation has been shown to promote neuroplasticity and increase dendritic spine density

4. Emotional Processing — Enhanced emotional processing and reduced rumination through altered brain network connectivity

Rationale for Depression in MCI/AD

Depression is common in MCI and AD, affecting up to 40-50% of patients, yet standard antidepressants have limited efficacy in this population. This trial explores a novel mechanism:

• Traditional antidepressants (SSRIs, SNRIs) target monoamine reuptake but show reduced effectiveness in neurodegenerative disease

• Psilocybin offers a different mechanism — directly modulating serotonin receptors and brain network dynamics

• Addressing an unmet need — Depression in MCI/AD worsens cognitive decline and quality of life

Pharmacokinetics and Metabolism

Absorption and Distribution

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is rapidly absorbed after oral administration, with peak plasma concentrations reached within 20-40 minutes. The compound has a relatively short half-life of approximately 1-2 hours for psilocybin itself, though the active metabolite psilocin has a half-life of 2-3 hours. Psilocybin is distributed throughout the body, including the brain, due to its lipophilic nature and ability to cross the blood-brain barrier.

Metabolic Pathway

The metabolic conversion of psilocybin to psilocin occurs primarily in the liver through alkaline phosphatase-mediated dephosphorylation. This process is remarkably efficient, with virtually all psilocybin converted to psilocin within minutes of ingestion. Psilocin is further metabolized through oxidation by monoamine oxidase (MAO) and subsequent glucuronidation for renal excretion. The relatively rapid metabolism and elimination of psilocybin and psilocin reduces concerns about prolonged drug exposure in elderly populations.

Drug-Drug Interactions

The metabolic pathway involving MAO has important implications for drug interactions. While psilocybin itself is not a potent MAO inhibitor, concurrent use with MAO inhibitors (MAOIs) requires caution due to potential serotonin syndrome. The trial explicitly excludes participants on MAO inhibitors, which aligns with standard psychedelic research protocols and ensures patient safety.

Special Considerations for Elderly Populations

Pharmacokinetic considerations in the elderly population include:

1. Reduced hepatic metabolism — Age-related decline in liver function may affect metabolism

2. Altered pharmacodynamics — Increased sensitivity to serotonergic effects

3. Renal function — Reduced glomerular filtration rate affects drug clearance

4. Body composition — Changes in fat distribution affect drug partitioning

The trial addresses these concerns through careful exclusion criteria and monitoring protocols.

Pharmacogenomics

Individual variation in drug response may be influenced by:

• CYP450 enzyme polymorphisms — Genetic variation in metabolizing enzymes

• Serotonin receptor variants — Genetic differences in 5-HT2A receptor structure

• Transporters — Genetic factors affecting drug uptake and distribution

Future precision medicine approaches may enable genotype-guided dosing.

Neurobiological Mechanisms

5-HT2A Receptor Signaling

The primary mechanism of psilocybin’s psychedelic effects involves activation of serotonin 5-HT2A receptors. These receptors are abundantly expressed in the prefrontal cortex, where they play crucial roles in modulating neural activity, synaptic plasticity, and cognitive processes. In the context of depression and AD, 5-HT2A receptor activation leads to:

1. G-protein signaling — Activation of phospholipase C (PLC) pathways, leading to increased intracellular calcium and downstream signaling cascades

2. Beta-arrestin recruitment — Alternative signaling that may contribute to desensitization and tolerance development

3. ERK/MAPK activation — Cell survival and plasticity pathways that may support neuroprotective effects

Default Mode Network Modulation

The default mode network (DMN) is a constellation of brain regions active during rest and internally-directed thought. In both depression and AD, the DMN shows hyperconnectivity and abnormal dynamics:

• Depression: Rumination and negative self-referential processing are associated with DMN hyperconnectivity

• AD: DMN disruption correlates with amyloid deposition and cognitive decline

Psychedelic compounds, including psilocybin, have been shown to disrupt DMN integrity while increasing global brain connectivity. This “network entropy” increase may support flexible thinking and emotional processing. Functional MRI studies have demonstrated that psilocybin administration leads to:

1. Reduced DMN activity and connectivity

2. Increased communication between previously segregated brain regions

3. Enhanced integration of global brain function

4. Long-lasting changes in brain network organization

Neuroplasticity Effects

Beyond acute network effects, psilocybin has demonstrated capacity to promote neuroplasticity—the brain’s ability to reorganize and form new neural connections. Research has shown:

• Dendritic spine growth — Increased spine density on pyramidal neurons in prefrontal cortex

• Synaptogenesis — Formation of new synaptic connections

• Angiogenesis — Growth of new blood vessels supporting neural tissue

• Enhanced BDNF signaling — Brain-derived neurotrophic factor elevation

These neuroplasticity mechanisms are particularly relevant for AD, where synaptic loss correlates with cognitive decline. By promoting neuroplasticity, psilocybin may support neural repair and cognitive recovery.

Anti-inflammatory Effects

Recent research suggests that psychedelics may exert anti-inflammatory effects through multiple pathways:

• TLR4 signaling — Psilocin can inhibit TLR4-mediated inflammatory responses

• Cytokine modulation — Reduced pro-inflammatory cytokine production

• Microglial regulation — Modulation of microglial activation states

Chronic neuroinflammation is a key contributor to AD pathogenesis, so anti-inflammatory effects could provide additional therapeutic benefit.

Study Design

Intervention Protocol

• Duration: 8-week treatment course

• Psilocybin sessions: Two administrations in weeks 4 and 6

  • First session: 15 mg/70 kg

  • Second session: 15 or 25 mg/70 kg (dose escalation at investigator discretion)

• Supportive care: Weekly psychological support throughout the study

Eligibility Criteria

Inclusion:

• MCI due to AD or early AD with mild severity (MMSE >18, MoCA <26)

• Depressive symptoms (CSDD ≥6 or GDS-SF ≥5)

• Stable acetylcholinesterase inhibitor dose for >6 weeks

• Stable SSRI/SNRI/bupropion for >2 months

• Availability of a close friend/family member as informant

Exclusion:

• Age >85 years

• Current antipsychotics or MAO inhibitors

• Cardiovascular conditions, seizure disorder, insulin-dependent diabetes

• Renal disease (creatinine clearance <40 ml/min)

• Liver enzyme elevation >2x ULN

• Psychiatric history: schizophrenia, psychotic disorder, bipolar I disorder

• First-degree relative with schizophrenia, psychotic disorder, or bipolar I disorder

• Past-year hallucinogen use

Safety Considerations in MCI/AD Population

Cardiovascular Risks

The trial excludes participants with significant cardiovascular conditions, reflecting known risks of psychedelic compounds. Psilocybin can cause transient increases in heart rate and blood pressure through serotonergic effects on the cardiovascular system. In healthy adults, these effects are typically mild and self-limiting. However, in older adults with AD, who may have pre-existing cardiovascular compromise, careful screening is essential.

Neurological Considerations

Given the baseline neurological vulnerability in AD, several safety considerations apply:

1. Seizure threshold — The trial excludes participants with seizure disorders, as psychedelics may lower seizure threshold

2. Cerebrovascular health — Exclusion criteria ensure participants do not have conditions increasing stroke risk

3. Cognitive reserve — The MMSE >18 threshold ensures participants have sufficient cognitive capacity to provide informed consent and communicate distress

Psychiatric Safety

The most significant safety concern with psychedelics in any population is the risk of adverse psychiatric reactions:

• Psychotic episodes — Individuals with personal or family history of psychotic disorders are excluded

• Anxiety reactions — Supportive setting and trained therapists can manage acute distress

• Persistent effects — The trial includes 2-week follow-up assessments to monitor for delayed effects

Drug Interactions

The exclusion criteria carefully address potential drug interactions:

• Acetylcholinesterase inhibitors — Must be stable for >6 weeks (e.g., donepezil, rivastigmine)

• Antidepressants — SSRI/SNRI/bupropion must be stable for >2 months

• Antipsychotics — Excluded due to potential interactions and confounding effects

• MAO inhibitors — Excluded due to serotonin syndrome risk

Comparison with Related Trials

Other Psilocybin-AD Trials

Several related trials are exploring psychedelics in neurodegenerative conditions:

Related Depression Trials in Elderly

This trial builds on established research in treatment-resistant depression:

Ethical Framework

Informed Consent Considerations

Given the cognitive impairment in the target population, enhanced consent procedures are essential:

1. Capacity assessment — Formal evaluation of decision-making capacity

2. Legally authorized representative — Involvement when appropriate

3. Ongoing consent — Repeated confirmation throughout study participation

4. Collateral consent — Family member engagement as study partner

Risk-Benefit Analysis

The trial balances potential benefits against risks:

Potential Benefits:

• Novel treatment for depression resistant to conventional approaches

• Potential cognitive benefits through neuroplasticity

• Improved quality of life

Potential Risks:

• Acute psychological distress

• Unknown long-term effects in AD population

• Interaction with disease progression

Historical Context

Psilocybin research in AD builds on a foundation of earlier work:

• 1960s-70s: Early psychedelic research was largely halted due to regulatory restrictions

• 2000s: Renaissance of psychedelic research began with improved protocols

• 2020s: Extension to special populations including elderly and neurological conditions

The current trial represents the systematic extension of psychedelic therapy to neurodegenerative disease, following established safety protocols from prior work in healthy and psychiatric populations.

Outcome Measures

Primary Outcomes

Secondary Outcomes

Exploratory Outcomes

Clinical Significance

This trial represents an important step in understanding:

1. Novel treatment paradigm — Psychedelic-assisted therapy for neurodegeneration-related depression

2. Safety in vulnerable population — First systematically evaluating psilocybin safety in MCI/AD

3. Mechanism exploration — Whether 5-HT2A agonism can address depression resistant to traditional approaches

4. Quality of life — Assessing whether psilocybin can improve overall wellbeing beyond mood

Implications for AD Treatment

If this trial demonstrates safety and efficacy, it could fundamentally change how depression is treated in AD:

• Disease modification — Neuroplasticity effects may slow cognitive decline

• Combination therapy — Psilocybin could be combined with existing AD treatments

• Personalized medicine — Biomarker-guided patient selection for treatment response

Broader Impact on Neuroscience

This research extends beyond AD to inform our understanding of:

• Brain network dynamics — How psychedelic-induced network changes relate to therapeutic outcomes

• Neuroinflammation — Anti-inflammatory mechanisms as treatment targets

• Aging brain — How the aging brain responds to psychedelic compounds

Regulatory Pathway

Positive results could accelerate:

• Expanded access programs — For patients with treatment-resistant depression in neurodegenerative disease

• Label expansions — Potential FDA approval for MCI/AD indication

• Clinical practice guidelines — Integration of psychedelic therapy into standard care

Patient Population Context

Depression in Neurodegenerative Disease

Depression affects approximately 40-50% of patients with MCI and AD, representing a significant comorbidity that worsens outcomes:

• Accelerated cognitive decline — Depression is associated with more rapid progression of cognitive impairment

• Increased mortality — Depression increases mortality risk through multiple mechanisms including suicide and reduced treatment adherence

• Caregiver burden — Depressed patients require more intensive caregiving support

• Treatment resistance — Traditional antidepressants show reduced efficacy in neurodegenerative populations

The underlying mechanisms of depression in AD include:

1. Neurotransmitter dysfunction — Loss of serotonergic and noradrenergic neurons

2. Neuroinflammation — Pro-inflammatory cytokines affecting mood regulation

3. Neuroanatomical changes — Damage to mood-regulating brain regions

4. Psychological burden — Awareness of cognitive decline and functional loss

Challenges in Treating Depression in AD

This trial addresses several key challenges:

1. Pharmacokinetic changes — Age-related alterations in drug metabolism require careful dosing

2. Drug interactions — Polypharmacy in elderly populations increases interaction risks

3. Cognitive effects — Many antidepressants can worsen cognitive function

4. Treatment resistance — Up to 50% of AD patients show inadequate response to traditional antidepressants

Psilocybin offers a fundamentally different approach that may overcome these limitations.

Research Team and Institution

Johns Hopkins Center for Psychedelic and Consciousness Research

The research team at Johns Hopkins is the world leader in psychedelic research:

• Founding director — Dr. Roland Griffiths has led psychedelic research since the 1990s

• Over 100 publications — Extensive track record in psilocybin safety and efficacy

• FDA-approved protocols — Multiple Phase 1 and 2 trials with regulatory approval

• Training program — Established training for psychedelic therapy practitioners

Collaborative Partners

The trial involves multiple partner organizations:

• Council On Spiritual Practices — Non-profit supporting psychedelic research

• Heffter Research Institute — Non-profit funding psilocybin research

• Data Safety Monitoring Board — Independent oversight of safety

Principal Investigators

The trial is led by experts in both psychedelic research and Alzheimer’s disease:

• Dr. Roland Griffiths — Professor of Psychiatry and Neuroscience, pioneering psilocybin researcher with over 20 years of experience

• Dr. Mary Ann Raghanti — Co-investigator specializing in aging and neurodegeneration

• Dr. Frederick Barrett — Psychology expert in psychedelic therapy protocols and safety

Infrastructure and Resources

The trial leverages substantial institutional resources:

1. Specialized treatment rooms — Designed for psychedelic therapy with comfortable, supportive environment

2. Monitoring equipment — Continuous vital sign monitoring during sessions

3. Emergency protocols — Established procedures for managing adverse events

4. Data management — Electronic data capture with rigorous quality control

Future Directions

Potential for Expanded Indications

If successful, this trial could pave the way for psychedelic therapy in:

1. Parkinson’s disease depression — Similar mechanisms and unmet need

2. Frontotemporal dementia — Behavioral variant with depression symptoms

3. Vascular dementia — Depression common in vascular cognitive impairment

4. Amyotrophic lateral sclerosis — Psychological support for terminal illness

Combination Approaches

Future research may explore:

• Psychotherapy integration — Combining psilocybin with cognitive behavioral therapy

• Cognitive enhancement — Pairing with cognitive training programs

• Disease-modifying drugs — Combination with AD-targeted therapeutics

• Repetitive dosing — Multiple treatment courses for sustained benefit

Biomarker Development

The exploratory outcomes may identify:

• Neuroimaging biomarkers — Predictive response to psychedelic treatment

• Genetic predictors — Pharmacogenomic factors affecting response

• Inflammatory markers — Blood-based predictors of treatment response

• Cognitive endpoints — Sensitive measures of treatment benefit

Long-term Follow-up Studies

Beyond this initial trial, future studies should examine:

1. Sustained efficacy — Duration of antidepressant effect over 6-12 months

2. Disease modification — Impact on AD progression rate

3. Cognitive outcomes — Whether neuroplasticity effects translate to cognitive benefit

4. Safety monitoring — Long-term psychological effects in vulnerable population

Implementation Science

If successful, implementation research will be needed to:

• Training programs — Develop certification for psychedelic therapy practitioners

• Facility requirements — Establish standards for treatment setting

• Cost-effectiveness — Evaluate economic value of psychedelic therapy

• Access equity — Ensure equitable access across populations

Related Compounds

Related Pages

• Alzheimer’s Disease

• Mild Cognitive Impairment

• Depression in Neurodegeneration

• Serotonin Signaling

• Psychedelics in Neurology

• Johns Hopkins University

External Links

• ClinicalTrials.gov

• Johns Hopkins Study Information